Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brain Cancer
Hudson licenses radiosensitizer IPdR
April 6th, 2004
Hudson Health Sciences, Inc., (HHS), a biopharmaceutical company headquartered in San Francisco, California, has licensed IPdR, a radiosensitizer, from Yale University and The Research Foundation of the State University of New York. IPdR is initially being developed as a radiation sensitizer for the treatment of certain types of brain cancers. Hudson Health Sciences anticipates commencing phase I trials during 2004. IPdR is a novel, orally available, halogenated dThd analogue and prodrug for IUdR, an intravenous tumor radiation sensitizer. A battery of preclinical studies concluded that IPdR is a superior radiosensitizer compared to IUdR in terms of...
Source: Cancer Weekly (2004-04-06)
|
